Eine Studie zum Medikament Selinexor mit Strahlentherapie bei Patienten mit neu diagnostiziertem diffusem intrinsischem Pontin (DIPG)-Gliom und hochgradigem Gliom (HGG)
Eine Phase-1/2-Studie mit Selinexor (KPT-330) und Strahlentherapie bei neu diagnostiziertem pädiatrischem diffusem intrinsischem Pontin-Gliom (DIPG) und hochgradigem Gliom (HGG)
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the event-free survival (EFS) distribution for diffuse midline glioma (DMG)/HGG patients and overall survival (OS) distribution for DIPG patients associated with selinexor plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3 K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy phase/phase II)
EXPLORATORY OBJECTIVE:
I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future studies.
OUTLINE: This is a phase I dose-escalation study of selinexor followed by a phase II study. (STRATUM DIPG AND STRATUM DMG CLOSED TO ACCRUAL 02/14/2025)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally (PO) on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a magnetic resonance imaging (MRI) and may undergo a biopsy during screening.
MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up.
After completion of study treatment, patients are followed every 3 months for year 1 (i.e., 3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and finally once yearly for years 4-5 of this study.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Kanada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Kanada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Christchurch, Neuseeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Neuseeland, 1145
- Starship Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Vereinigte Staaten, 85016
- Phoenix Childrens Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Vereinigte Staaten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90027
- Children's Hospital Los Angeles
-
Madera, California, Vereinigte Staaten, 93636
- Valley Children's Hospital
-
Oakland, California, Vereinigte Staaten, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Vereinigte Staaten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Vereinigte Staaten, 94304
- Lucile Packard Children's Hospital Stanford University
-
San Diego, California, Vereinigte Staaten, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Vereinigte Staaten, 33176
- Miami Cancer Institute
-
Orlando, Florida, Vereinigte Staaten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Vereinigte Staaten, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Vereinigte Staaten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Comprehensive Cancer Center
-
Peoria, Illinois, Vereinigte Staaten, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Riley Hospital for Children
-
-
Iowa
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Vereinigte Staaten, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Vereinigte Staaten, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Vereinigte Staaten, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Albany Medical Center
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Syracuse, New York, Vereinigte Staaten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Vereinigte Staaten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Vereinigte Staaten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Vereinigte Staaten, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Vereinigte Staaten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Vereinigte Staaten, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Cook Children's Medical Center
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78207
- Children's Hospital of San Antonio
-
Temple, Texas, Vereinigte Staaten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Vereinigte Staaten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Children's Hospital of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
PRE ENROLLMENT: Patients must be =< 25 years of age at the time of enrollment on APEC14B1 part A central nervous system (CNS)/high grade glioma (HGG) pre-enrollment eligibility screening
-
Please note:
- This required age range applies to pre-enrollment eligibility for all HGG patients. Individual treatment protocols may have different age criteria.
- Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are >= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1).
-
-
PRE ENROLLMENT: Patient is suspected of having localized, newly diagnosed HGG, excluding metastatic disease, OR patient has an institutional diagnosis of DIPG
- Please note: there are specific radiographic criteria for DIPG patient enrollment on ACNS1821 (Step 1)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors: Patients and/or their parents or legal guardians must have signed informed consent for eligibility screening on APEC14B1 Part A.
- For patients with DIPG: Patients and/or their parents or legal guardians must have signed informed consent for ACNS1821.
- Note: As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors only, the specimens obtained at the time of diagnostic biopsy or surgery must be submitted through APEC14B1 ASAP, preferably within 5 calendar days of definitive surgery
-
STEP 1: Patients must be >= 12 months and =< 21 years of age at the time of enrollment
-
STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG).
-
STEP 1: Stratum DIPG (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial T2 weighted image, are eligible. No histologic confirmation is required.
- Patients with pontine tumors that do not meet radiographic criteria for typical DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine cross-sectional area with or without extrapontine extension) are eligible if the tumors are biopsied and proven to be high-grade gliomas (such as anaplastic astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS], and/or H3 K27M-mutant) by institutional diagnosis.
-
STEP 1: Stratum DMG (with H3 K27M mutation) (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
- Note: Patients need not have either measurable or evaluable disease, i.e., DMG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in non-midline structures (e.g., cerebral hemispheres), these patients will be considered part of Stratum DMG.
-
STEP 1: Stratum HGG (without H3 K27M mutation)
-
Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
-
Please note:
- Patients who fall in this category and who are >= 18 years of age are not eligible due to another standard-of-care regimen (radiation/temozolomide) that is available
- Patients need not have either measurable or evaluable disease, i.e., HGG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment
-
-
STEP 1: Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =<16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
STEP 1: Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to step 1 enrollment)
-
STEP 1: Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to step 1 enrollment)
-
STEP 1: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to step 1 enrollment)
-
STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to step 1 enrollment) or
A serum creatinine based on age/sex as follows (within 7 days prior to step 1 enrollment):
-
Age / Maximum Serum Creatinine (mg/dL)
-
1 to < 2 years / male: 0.6; female: 0.6
-
2 to < 6 years / male: 0.8; female: 0.8
-
6 to < 10 years / male: 1; female: 1
-
10 to < 13 years / male: 1.2; female: 1.2
-
13 to < 16 years / male: 1.5; female: 1.4
-
>= 16 years / male: 1.7; female: 1.4
- STEP 1: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.
- STEP 1: Serum amylase =< 1.5 x ULN
- STEP 1: Serum lipase =< 1.5 x ULN
- STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination.
- STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
- STEP 1: Patients must be enrolled and protocol therapy must begin no later than 31 days after the date of radiographic diagnosis (in the case of non-biopsied DIPG patients only) or definitive surgery, whichever is the later date (Day 0).
-
For patients who have a biopsy followed by resection, the date of resection will be considered the date of definitive diagnostic surgery. If a biopsy only was performed, the biopsy date will be considered the date of definitive diagnostic surgery.
Exclusion Criteria:
-
STEP 1: Patients must not have received any prior therapy for their central nervous system (CNS) malignancy except for surgery and steroid medications.
-
STEP 1: Patients who are currently receiving another investigational drug are not eligible.
-
STEP 1: Patients who are currently receiving other anti-cancer agents are not eligible.
-
STEP 1: Patients >=18 years of age who have H3 K27M-wild type HGG.
-
STEP 1: Patients who have an uncontrolled infection.
-
STEP 1: Patients who have received a prior solid organ transplantation.
-
STEP 1: Patients with grade > 1 extrapyramidal movement disorder.
-
STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts.
-
STEP 1: Patients with metastatic disease are not eligible; MRI of spine with and without contrast must be performed if metastatic disease is suspected by the treating physician.
-
STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the exception of H3 K27M-mutant bithalamic tumors.
-
STEP 1: Patients who are not able to receive protocol specified radiation therapy.
-
STEP 1:
- Female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities.
- Lactating females are not eligible unless they have agreed not to breastfeed their infants. It is not known whether selinexor is excreted in human milk.
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
- Sexually active patients of reproductive potential are not eligible unless they have agreed to use two effective methods of birth control (including a medically accepted barrier method of contraception, e.g., male or female condom) for the duration of their study participation and for 90 days after the last dose of selinexor. Abstinence is an acceptable method of birth control.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Treatment (selinexor and radiation therapy)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening. MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up. |
Undergo radiation therapy
Andere Namen:
Undergo a MRI
Andere Namen:
Undergo a biopsy
Andere Namen:
Given orally
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum tolerated dose
Zeitfenster: From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
Defined as the highest dose of selinexor in combination with standard of care radiation therapy that does not cause unacceptable side effects. |
From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
|
Event free survival (EFS)
Zeitfenster: From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse midline glioma/ high grade glioma patients. EFS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
|
Overall Survival (OS)
Zeitfenster: From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse intrinsic pontine glioma patients. The OS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
|
Overall response rate
Zeitfenster: Up to 5 years
|
Defined as the proportion of patients whose best response is partial response or complete response. |
Up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Adam L Green, Children's Oncology Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Gliom
- Untersuchungstechniken
- Therapeutika
- Handhabung von Proben
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Zytologische Techniken
- Zytodiagnose
- Physikalische Phänomene
- Diagnosetechniken, chirurgisch
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Strahlentherapie
- Strahlung
- Biopsie
- Magnetresonanzspektroskopie
- Selinexor
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2021-11337
- U10CA180886 (US NIH Stipendium/Vertrag)
- NCI-2021-11337 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- ACNS1821 (Andere Kennung: CTEP)
- ACNS1821 (Andere Kennung: Children's Oncology Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .